JP2013525332A5 - - Google Patents

Download PDF

Info

Publication number
JP2013525332A5
JP2013525332A5 JP2013505469A JP2013505469A JP2013525332A5 JP 2013525332 A5 JP2013525332 A5 JP 2013525332A5 JP 2013505469 A JP2013505469 A JP 2013505469A JP 2013505469 A JP2013505469 A JP 2013505469A JP 2013525332 A5 JP2013525332 A5 JP 2013525332A5
Authority
JP
Japan
Prior art keywords
strand
sequence
composition
nucleotides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013505469A
Other languages
English (en)
Japanese (ja)
Other versions
JP5857378B2 (ja
JP2013525332A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/056299 external-priority patent/WO2011131707A1/en
Publication of JP2013525332A publication Critical patent/JP2013525332A/ja
Publication of JP2013525332A5 publication Critical patent/JP2013525332A5/ja
Application granted granted Critical
Publication of JP5857378B2 publication Critical patent/JP5857378B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013505469A 2010-04-23 2011-04-20 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 Expired - Fee Related JP5857378B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32737910P 2010-04-23 2010-04-23
US61/327,379 2010-04-23
US33339810P 2010-05-11 2010-05-11
US61/333,398 2010-05-11
PCT/EP2011/056299 WO2011131707A1 (en) 2010-04-23 2011-04-20 ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014085797A Division JP5976032B2 (ja) 2010-04-23 2014-04-17 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物

Publications (3)

Publication Number Publication Date
JP2013525332A JP2013525332A (ja) 2013-06-20
JP2013525332A5 true JP2013525332A5 (https=) 2014-06-05
JP5857378B2 JP5857378B2 (ja) 2016-02-10

Family

ID=44227799

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2013505469A Expired - Fee Related JP5857378B2 (ja) 2010-04-23 2011-04-20 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2014085797A Expired - Fee Related JP5976032B2 (ja) 2010-04-23 2014-04-17 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2016141325A Expired - Fee Related JP6290316B2 (ja) 2010-04-23 2016-07-19 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2018019887A Expired - Fee Related JP6577073B2 (ja) 2010-04-23 2018-02-07 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2019150816A Pending JP2019214604A (ja) 2010-04-23 2019-08-21 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2021165417A Pending JP2022003089A (ja) 2010-04-23 2021-10-07 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2014085797A Expired - Fee Related JP5976032B2 (ja) 2010-04-23 2014-04-17 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2016141325A Expired - Fee Related JP6290316B2 (ja) 2010-04-23 2016-07-19 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2018019887A Expired - Fee Related JP6577073B2 (ja) 2010-04-23 2018-02-07 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2019150816A Pending JP2019214604A (ja) 2010-04-23 2019-08-21 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
JP2021165417A Pending JP2022003089A (ja) 2010-04-23 2021-10-07 ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物

Country Status (15)

Country Link
US (10) US8344127B2 (https=)
EP (3) EP3431604A1 (https=)
JP (6) JP5857378B2 (https=)
KR (4) KR20180033606A (https=)
CN (2) CN102985544A (https=)
AR (1) AR081082A1 (https=)
AU (1) AU2011244335B2 (https=)
BR (1) BR112012027080A2 (https=)
CA (2) CA3098080A1 (https=)
DK (1) DK2561077T3 (https=)
EA (1) EA034363B1 (https=)
ES (1) ES2574204T3 (https=)
MX (2) MX350595B (https=)
TW (1) TWI434692B (https=)
WO (1) WO2011131707A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3098080A1 (en) 2010-04-23 2011-10-27 Arrowhead Research Corporation Organic compositions to treat beta-enac-related diseases
CN102397279B (zh) * 2011-11-18 2012-10-31 新乡医学院 无羁萜-3β-醇在制备抗血管性痴呆的药物中的应用
EP2852668B1 (en) * 2012-07-12 2016-04-27 ProQR Therapeutics II B.V. Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell
EP3110381B1 (en) 2014-02-28 2020-07-15 Attends Healthcare Products, Inc. Absorbent article with multi-layer folded absorbent core
WO2018027550A1 (en) * 2016-08-09 2018-02-15 Shanghai Yao Yuan Biotechnology Co., Ltd. Methods and compositions for appetite control and weight management
BR112019012060A2 (pt) 2016-12-14 2020-03-10 Attends Healthcare Products Inc. Laminados absorventes, núcleos absorventes e artigos descartáveis utilizando os laminados absorventes e métodos relacionados
ES3019585T3 (en) 2018-05-28 2025-05-20 Attends Healthcare Products Inc Dryness layer laminate for absorbent articles
CN109364248B (zh) * 2018-10-16 2021-05-18 哈尔滨医科大学 ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用
TW202130809A (zh) * 2019-10-29 2021-08-16 美商愛羅海德製藥公司 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
US20230136960A1 (en) * 2020-03-19 2023-05-04 Nature's Toolbox, Inc. Novel MRNA-Based COVID-19 Multi-Valent Vaccine and Methods of Scaled Production of the Same
CN114149492A (zh) * 2020-08-21 2022-03-08 中国人民解放军军事科学院军事医学研究院 一种用于预防甲型流感病毒感染的HA-mRNA疫苗

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696561B1 (en) 1909-07-09 2004-02-24 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
US9459259B2 (en) * 2001-05-01 2016-10-04 Senomyx, Inc. Electrophysiological assays using oocytes that express human enac and the use of phenamil to improve the effect of enac enhancers in assays using membrane potential reporting dyes
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2002100435A1 (en) 2001-06-11 2002-12-19 Centre Hospitalier Universitaire De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
CA2456977C (en) 2001-08-16 2011-06-07 The Trustees Of The University Of Pennsylvania Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
AU2002364612A1 (en) 2001-12-31 2003-07-24 Algos Therapeutics, Inc. METHODS AND MATERIALS FOR MODULATING ENaC-BETA
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
MXPA05003287A (es) 2002-09-28 2005-07-05 Massachusetts Inst Technology Influenza terapeutica.
EP2305812A3 (en) * 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
ES2343318T3 (es) 2002-11-26 2010-07-28 University Of Massachusetts Administracion de arnsis.
US20040208921A1 (en) 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
ES2559828T3 (es) 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. ARN de interferencia encapsulado en lípidos
CN1845993B (zh) 2003-08-28 2010-06-23 诺瓦提斯公司 具有平端和3＇修饰的干扰rna双链体
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
HUE027349T2 (en) * 2005-09-16 2016-09-28 Devgen Nv Double-stranded RNA as an insecticide
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US7389426B2 (en) 2005-11-29 2008-06-17 Research In Motion Limited Mobile software terminal identifier
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
BRPI0811170B8 (pt) 2007-05-22 2021-05-25 Arcturus Therapeutics Inc oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
WO2009082817A1 (en) 2007-12-27 2009-07-09 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
CA3098080A1 (en) 2010-04-23 2011-10-27 Arrowhead Research Corporation Organic compositions to treat beta-enac-related diseases

Similar Documents

Publication Publication Date Title
JP2013525332A5 (https=)
JP2013514321A5 (https=)
JP2014525435A5 (https=)
JP2015517466A5 (https=)
JP2016511256A5 (https=)
US20210238601A1 (en) Oligonucleotide Conjugates
Ma et al. Recent advances of discrete coordination complexes and coordination polymers in drug delivery
JP7009356B2 (ja) ハンチンチンｍＲＮＡをターゲティングするオリゴヌクレオチド化合物
JP7618229B2 (ja) Ｓｎｐを標的化する修飾オリゴヌクレオチド
WO2009120887A3 (en) Compositions and methods for tissue-specific rnai delivery in vivo
JP2018512060A5 (https=)
ES2984631T3 (es) Composiciones y procedimientos para disminuir la expresión de tau
JP2017518045A5 (https=)
JP2016116520A5 (https=)
JP2015500835A5 (https=)
US20110117026A1 (en) Methods and compositions for the delivery of bioactive compounds
JP2009517048A5 (https=)
JP2007533323A (ja) 哺乳類の細胞における遺伝子発現を調節するための、二本鎖ｒｎａまたは二本鎖ハイブリッド核酸の送達を増強するための方法および組成物
JP2015523854A5 (https=)
JP2012050438A5 (https=)
JP2019503199A5 (https=)
JP2007525454A5 (https=)
WO2015168635A2 (en) Compositions and methods for modulating complement factor b expression
JP2015536132A5 (https=)
JP2011529912A5 (https=)